Research programme: ROR gamma receptor modulators - Karo Pharma/Pfizer
Latest Information Update: 28 Dec 2018
Price :
$50 *
At a glance
- Originator Karo Bio; Pfizer
- Developer Karo Pharma AB; Pfizer
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for research development in Autoimmune-disorders in Sweden
- 21 Dec 2016 Early research development is ongoing in Sweden (Karo Pharma pipeline, December 2016)
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in Sweden